Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in investor conferences in May 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in investor conferences in May 2024. They will be attending events like the BofA Securities 2024 Health Care Conference and the TD Cowen 5th Annual Oncology Innovation Virtual Summit. The Company aims to showcase its progress in developing small molecule medicines through targeted protein degradation (TPD).
Details
News Market Reaction – KYMR
The recorded move for KYMR in the trading session of this news was +0.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
- BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; and
- TD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.